Funded Projects

This team will use their Neuroscience:Translate award to develop a large-scale bi-directional neural interface that will restore high-fidelity vision to people blinded by retinal degeneration.

This team will use their Neuroscience:Translate award to employ a novel therapeutic technique to correct pathogenic mutations causing Parkinson’s disease.

This team will use their Neuroscience:Translate award to develop an entirely new class of ischemic stroke treatment device that will lead to improved clot extraction to improve the success of endovascular thrombectomy.

This team will use their Neuroscience:Translate award to develop the first wearable ultrasound (US) device for the treatment of inflammatory diseases, such as Rheumatoid Arthritis (RA) and Inflammatory Bowel Disease.

We propose a new line of research whose goal is to examine the druggability of a protein-protein interface involving ApoE, an apolipoprotein whose gene variants represent the strongest genetic risk factor for AD.

People with Parkinson’s Disease (PD) have different types of bacteria in their guts compared to people without neurological diseases. We will study which gut bacteria for people with PD to gain a better understanding of how gut bacteria contribute to inflammation in the body and in the brain or people with this condition. 

We propose to apply mass spectrometry techniques to measure BHB-Phe and other KD metabolites in children undergoing KD for refractory epilepsy at Stanford. Further, in a mouse model of refractory genetic epilepsy, we will compare targeted BHB-Phe treatment to full KD treatment using transcriptomics, EEG assessment of seizures and cognitive testing.

Why do all our brains mature and age in different ways, leading to different cognitive and behavioral outcomes? We envision a novel method that “copies” the information from the RNAs made by the neurons to sensor RNAs we artificially introduce into live animals. 

In this study, we aim to (i) perform a feasibility study to determine the acceptance and feasibility of performing such recordings in the AN and ARFID eating disorders population and (ii) test the hypothesis that the electrophysiologic monitoring of the brain and stomach is associated with a clinically validated behavioral measure of interoception involving water distention of the stomach.

This team is developing a small molecule that targets a voltage-gated ion channel within the inner ear for the symptomatic relief of peripheral vertigo attacks. They will use their Neuroscience:Translate award to further develop this molecule to restore normal function and improve activities of daily living for patients experiencing peripheral vertigo.

This team has identified a promising protein-based therapeutic to improve stroke recovery.  The team will use the Neuroscience:Translate award to identify key components of this protein to maximize its therapeutic potential for stroke treatments.

This team recently identified a selective biomarker of inflammation-promoting immune cells in the central nervous system. They will use their Neuroscience:Translate award to develop non-invasive molecular imaging strategies to distinguish between harmful (pro-inflammatory) and helpful (anti-inflammatory) immune cells in patients with Multiple sclerosis (MS).

This team has developed a new therapy for patients with spinal cord injury, involving injection into the spinal cord of patient-derived stem cells within an engineered protective gel. They will use their Neuroscience:Translate award to further test and develop this novel therapy in preparation for first-in-human clinical trials. 

This team recently discovered that a small molecule they had originally developed to treat Parkinson’s disease can also reduce the volume of glioblastoma tumors – the most common form of aggressive brain tumor — by targeting the mitochondrial protein Miro1. They will use their Neuroscience:Translate award to study the mechanisms of the compound’s anti-tumor action and prepare to apply for investigational-new-drug status to move this discovery toward the clinic.

Our goal is to develop the next generation of neural interfaces that match the resolution and performance of the biological circuitry. We will focus on two signature efforts to spearhead the necessary advances: high-density wire bundles for electrical recording and stimulation, and analog and digital bi-directional retinal prostheses for restoration of vision.

The Stanford Brain Rejuvenation Project is an initiative by leading aging researchers, neuroscientists, chemists, and engineers to understand the basis of brain aging and rejuvenation and how they relate to neurodegeneration.

Combining a detailed understanding of brain circuits with technology that modulates neural activity to develop improved ways of treating mental health conditions.

The goal is to forge an inter-disciplinary collaboration between physicists, biologists, chemists, and translational medical scientists by inventing new ways of visualizing the brain, from individual molecules to neuronal circuits to entire brain regions, from a normally functioning neuron to a diseased brain.

Creating an incubator for next-generation neural interface platforms.

Developing technology to interface with the brain and create intelligent prosthetics.

Breaches barriers in our understanding of stroke to develop therapies and improve stroke recovery.